Schering-Plough wins US dismissal of Intron A/Temodar off-label suit
This article was originally published in Scrip
Executive Summary
A US federal court has dismissed a class action lawsuit that alleged Schering-Plough had illegally marketed Intron A (interferon alfa-2b) and Temodar (temozolomide) for off-label use.